Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates Statistically Significant Improvements I
Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p<0.0001), the first and only statistically significant placebo-c